68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy.

The study aimed to summarize clinical characteristics associated with Gallium-68-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (68Ga-PSMA PET/CT) scans as patients were restaged for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or external beam radiotherapy (EBRT). Our analyses included multiple cox regression analyses. The study evaluated 95 patients with rising values of PSAs after RP and after EBRT. Sixty 63% of patients had a positive 68Ga-PSMA PET/CT scan. Twelve patients (13%) had a positive site in the prostate bed, 29 patients (30%) had a positive site in the regional lymph nodes, and 19 (20%) had positive sites in distant organs. After four years follow-up, 21 patients (22%) died. Using multiple Cox regression analyses, the number of positive sites on the 68Ga-PSMA PET/CT scan significantly predicted overall survival (OS) (p = 0.0001), whereas risk score and regional locations of the positive sites were not significant in the multiple Cox regression analyses. Our study indicates that the specific findings of 68Ga-PSMA PET/CT scans are important because detailed findings of the scans predict the outcome after salvage treatment of patients with PSA relapse examined with 68Ga-PSMA PET/CT scans.

1. Introduction

A quarter to half of patients with prostate cancer undergoing radical prostatectomy (RP) who had an initial decline of prostate-specific antigen (PSA) to unmeasurable levels later experience a rise of PSA levels [1,2,3]. Additionally, many patients treated with external beam radiotherapy (EBRT) who demonstrate a decline of PSA levels to low nadir PSA levels later experience a rise of PSA levels [4].

With regards to patients with PSA (“biochemical”) relapse and with a long doubling time of the PSA (PSADT) >12 months before they undergo a 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT) scan, and with cancers that have a low International Society of Pathology (ISUP) grade 1, few given salvage treatment progress to metastatic disease and cancer-specific death [1,2,5,6,7,8].

In contrast, many patients with PSA relapse who have a short PSADT <3 months and cancers that have a high ISUP grade 5 progress to metastatic cancer and cancer-specific death despite salvage treatment. Compared with conventional imaging modalities such as CT and bone scans, the 68Ga-PSMA PET/CT scan has a relatively high sensitivity, especially for patients with PSA relapse and PSA levels <2 ng/mL [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26]. Today, the Federal Drug Administration (FDA) in the USA and many guidelines recommend that urologists and oncologists examine patients with PSA relapse with 68Ga-PSMA PET/CT [27,28,29,30].

Clinical characteristics before and at the imaging with 68Ga-PSMA PET/CT of the examined patients may be associated with the finding of positive sites [31,32,33,34,35,36,37,38]. Detection of PSMA-avid lesions is important as urologists and oncologists change the planned treatment for up to half of the patients examined with 68Ga-PSMA PET/CT [39,40].

However, publications on 68Ga-PSMA PET/CT scans differ in their reported findings. Further, most publications do not report the numbers or the regional locations of positive sites, or report whether the numbers or the regional locations of positive sites predict the overall survival (OS) for the patients. Thus, it is important to have better insight regarding the outcome following restaging with 68Ga-PSMA PET/CT.

Accordingly, our study of patients with PSA relapse aimed: (1) at evaluating whether clinical characteristics before or at restaging relate to findings on 68Ga-PSMA PET/CT; (2) at summarizing the numbers and regional locations of positive sites on 68Ga-PSMA PET/CT scans; and (3) at evaluating whether the number and locations of positive sites predict OS.

2. Material and Methods

2.1. Patients

Our investigation reports 95 patients with PSA relapse treated at the University of Ankara, Turkey. Our study added information to those previously published [41]. The patients had histologically/cytologically proven prostate cancer. They had undergone either EBRT or RP with or without lymph node dissection (LND), with or without adjuvant EBRT, and with or without adjuvant androgen deprivation therapy (ADT), as shown in Table 1. PSA levels (ng/mL) were determined with an ultrasensitive PSA assay and were most often reported with two decimals [42].

Table 1

Patient characteristics.

Patient Characteristic		No pts	MedianValue	Lower and Upper IQ	Total Range
		95
Age (years)			68	64–72	55–87
Initial TNM staging	T1	6
	T2	53
	T3	18
	N0	72
	N1	23
ISUP score	1	9
	2–3	32
	4	27
	5	26
Risk	Low	11
	Intermediate	10
	High	54
Initial treatment	RP	45
	RP and adjuvant ADT	49
	RP and adjuvant EBRT	14
	EBRT
Relapse-free interval until PSA relapse (mos)			24	13–40	4–156
PSADT (mos)			10.6	4.5–48	1–168
Time from the latest PSA before the 68Ga-PSMA PET/CT to the scan			15	11–19	6–27
PSA at 68Ga-PSMA PET/CT (ng/mL)			5.7	1.2–12.6	0.10–155.6
68Ga-PSMA PET/CT sites	negative		35
	Prostate bed	12
	Regional lymph nodes	29
	Distant organs	19
Number of positive sites on 68Ga-PSMA PET/CT	0	35
	1	24
	2	13
	3	12
	4	5
	5	3
	7	2
Treatment after the 68Ga-PSMA PET/CT	Active surveillance	7
	Salvage radiotherapy	36
	Docetaxel	31
	Abiraterone/Enzalutamide	21

Abbreviations: ADT = androgen deprivation therapy, EBRT = external beam radiotherapy, ISUP = International Society of Urologic Pathology, IQ = interquartile, mos = months, no = number, pts = patients, PSADT = prostate-specific antigen doubling time, RP = radical prostatectomy, TNM = tumor, nodes, and metastases.

After RP, PSA levels typically had fallen to unmeasurable PSA levels. Similarly, after EBRT, PSA levels had typically been lowered to low nadir PSA levels. Later all patients had rising PSA levels. The rise of PSA at PSA relapse was documented in ≥3 PSA determinations carried out with ≥2 week intervals. None of the patients had had a rise of PSA due to PSA flare. The time interval between the latest PSA determination before the 68Ga-PSMA PET/CT and the scans was median 15 days.

2.2. 68Ga-PSMA PET/CT

The university in Ankara carried out the 68Ga-PSMA PET/CT scans between June 2015 and December 2018. The patients underwent 68Ga-DOTAGA-(1.y)fk(Sub-KuE) (68Ga-PSMA PET/CT) imaging and therapy (I&T) imaging as previously described [41,43]. The intravenously injected 68Ga activity was 111–185 MBq 68Ga-PSMA. Whole body 68Ga-PSMA PET/CT scans were obtained 45–60 min after the injection.

Attenuation-corrected PET/CT fusion images were reviewed in transaxial, coronal, and sagittal planes using Advanced Workstation Volumeshare 5 (GE Medical Systems, Houston, Pennsylvania, USA). Two experienced specialists in nuclear medicine evaluated semi-quantitatively the images according to the maximal standardized uptake values (SUVmax) in selected sites.

The specialists in nuclear medicine considered any focal 68Ga-PSMA uptake higher than the background uptake that did not correspond to physiologic retention of 68Ga-PSMA in organs or structures as positive for the malignancy. The specialists in nuclear medicine also recorded the number of positive sites on the 68Ga-PSMA PET/CT scans.

2.3. Definitions

The aggressiveness of the prostate cancers was classified as the ISUP grade at diagnosis of the primary cancer. ISUP grade 1 corresponds to a Gleason score ≤6, ISUP grade 3 corresponds to a Gleason score 4+3 (a total of 7), ISUP grade 4 corresponds to a Gleason score 8, and ISUP grade 5 corresponds to Gleason scores 9 and 10 [44]. At RP, the estimate of the prognosis of the patients is summarized as low, intermediate, and high risk, as described previously [45].

For patients who had undergone RP and had had a decline of PSA levels after RP to unmeasurable levels, a PSA relapse was defined as rising PSA levels to >0.20 ng/mL [46]. For patients who had undergone EBRT and had had a decline of PSA levels after the EBRT to low nadir levels, PSA relapse was defined as rising PSA levels to >2 ng/mL above the nadir PSA levels [47]. Rising PSA levels were defined as rising PSA levels determined in ≥3 PSA measurements carried out with least ≥2 week intervals.

As for patients treated with RP with or without adjuvant EBRT, the relapse-free interval was the time from RP with or without adjuvant EBRT to the 68Ga-PSMA PET/CT. For patients treated with EBRT, the relapse-free interval was the time from end of the EBRT to the restaging 68Ga-PSMA PET/CT. ADT were lutein-hormone releasing hormone (LHRH) agonists and did not include third generation androgen receptor (AR) pathway inhibitors such as abiraterone, enzalutamide, apalutamide, or darolutamide.

PSADT was defined as the time estimated for a doubling of the PSA levels. PSADT was calculated based on a calculator website from the Memorial Sloan Kettering Cancer Center [48]. Previous studies of patients with PSA relapse found that those with a high ISUP grade ≥4 and a short PSADT <12 months had a high risk of death from prostate cancer [1,2,5,7].

We classified the 68Ga-PSMA PET/CT findings according to a PET tumor, nodes, and metastases (TNM) classification [49]. We judged the extent of the prostate cancer by the most advanced positive regional location on the 68Ga-PSMA PET/CT. A local positive site referred to positive sites limited to the prostate bed as PET T. Metastases in pelvic lymph nodes were positive sites in the pelvic lymph nodes with or without local positive sites as PET N.

Metastases in extra-pelvic lymph nodes were positive sites in retroperitoneal and/or supra-diaphragmatic lymph nodes, with or without positive local sites, and with or without pelvic lymph node sites as PET M1a. Bone metastases were positive sites in bones with or without positive local sites, with or without pelvic lymph node sites, and with or without extra pelvic lymph node sites as PET M1b.

Metastases in visceral organs were positive sites in the lungs, liver, or brain, with or without local sites, with or without pelvic lymph node sites, with or without extra pelvic lymph node sites, and with or without sites in bones as PET M1c.

Oligometastatic prostate cancer was defined as one to three metastatic positive sites on imaging modalities irrespective of whether the positive sites were in the prostate bed, regional lymph nodes, or in distant organs [50]. Patients with more than three positive metastatic sites were defined to have polymetastatic prostate cancer.

Clinical confirmation of the diagnosis on the 68Ga-PSMA PET/CT scan implied that patients with a reduction of PSA had a reduction in the positive sites and patients with a rising PSA had increasing number or size of the positive sites.

2.4. Salvage Treatment

Some patients with negative 68Ga-PSMA PET/CT scans were followed with active surveillance. Other patients were given salvage EBRT to the prostate bed. Patients with positive sites in the prostate bed were given salvage EBRT to the prostate bed. Patients with positive sites in lymph nodes or bone were treated either with chemotherapy such as docetaxel or third generation androgen receptor pathway inhibitors such as abiraterone or enzalutamide. The patients were rarely given second line systemic treatment.

2.5. Statistical Methods

Our study did not substitute missing data. We evaluated whether clinical characteristics had statistically significant associations with positive sites on 68Ga-PSMA PET/CT. The logistic regression analysis regarded positive or negative findings on the 68Ga-PSMA PET/CT scans as dependent variables and both categorical and continuous predictors (clinical characteristics) as independent variables. An initial full multiple logistic regression model included all potentially relevant clinical characteristics. Backwards elimination excluded variables that were insignificant in multiple logistic regression analyses.

We did not include variables that were highly correlated in the multiple logistic regression analysis, even if the variables were significant in univariate logistic regression analysis. We evaluated the significance of difference in overall survival (OS) between groups of patients with log rank tests and multiple Cox analysis tests. All statistical tests were two-sided. We considered a p value <0.05 as statistically significant.

We carried out the statistical analyses with use of Stata 16 (Stata corporation, College Station, TX 77845, USA).

3. Results

3.1. Initial Treatment

The 95 patients were median 68 years old, as shown in Table 1. Patients treated with RP who had ISUP grade 5 cancers especially were often given adjuvant ADT after initial RP (21 of 27 patients with ISUP grade 5 vs. 22 of 68 patients with ISUP grade ≤4, p <0.0005, chi2 test). Adjuvant ADT was also given to a relatively large number of patients with lymph node metastases (LNM) (16 of 23 patients with LNM vs. 27 of 72 patients without LNM, p = 0.007, chi2 test). The adjuvant ADT was LHRH agonists and not a combination of ADT and third-generation AR pathway inhibitors.

Patients with an ISUP grade ≥4 had shorter PSADT at PSA relapse than patients with an ISUP grade ≤3 (p = 0.003, Kruskal–Wallis test). The time span from the most recent PSA before the 68Ga-PSMA PET/CT to the scan was median 15 days.

3.2. 68Ga-PSMA PET/CT

At the time of the 68Ga-PSMA PET/CT, the median PSA level of the patients was 5.7 ng/mL. Six of 76 patients (9%) who had undergone RP had PSA levels before the 68Ga-PSMA PET/CT scan of <0.4 ng/mL. Eight of 19 patients (40%) who had been treated with EBRT had PSA levels before the 68Ga-PSMA PET/CT scan of <4 ng/mL.

Sixty patients (63%) had a positive 68Ga-PSMA PET/CT scan. These patients had 7.5 times higher median PSA levels before the 68Ga-PSMA PET/CT scan than the 35 patients with a negative 68Ga-PSMA PET/CT scan (median 11.0 vs. 1.4 ng/mL, p = 0.0001, Kruskal–Wallis test). Twelve patients (13%) had a positive site in the prostate bed, 29 patients (30%) had a positive site in pelvic lymph nodes, and 19 (20%) had positive sites in distant organs.

Four patients had their 68Ga-PSMA PET/CT findings confirmed histopathologically, whereas 91 patients had their positive findings confirmed by the clinical course after the 68Ga-PSMA PET/CT scan.

Adjuvant ADT was related to the 68Ga-PSMA PET/CT findings (p = 0.01, chi2 test). Patients with a short PSADT <10 months more often had a high-risk score than patients with a longer PSADT (p < 0.0005, Kruskal–Wallis test). In contrast, the initial RP and EBRT were not significantly related to the 68Ga-PSMA PET/CT findings (p = 0.097, chi2 test).

A third of the patients had oligometastatic prostate cancer on the 68Ga-PSMA PET/CT scan and another third of the patients had polymetastatic prostate cancer, as shown in Table 1.

3.3. Prediction of Positive Sites on 68Ga-PSMA PET/CT

Patients with high risk at diagnosis had a higher number of positive sites on 68Ga-PSMA PET/CT than patients with low and intermediate risk, as shown in Figure 1.

Figure 1

Number of positive sites on 68Ga-PSMA PET/CT scan increased with high risk score.

Using multiple logistic regression analysis, PSADT was significant for positive findings with 68Ga-PSMA PET/CT, as shown in Table 2. In contrast, ISUP grade and risk score were significant in univariate logistic regression analyses for positive sites on the 68Ga-PSMA PET/CT scan, but not in multiple logistic regression analyses. Further, in univariate logistic regression analysis, many clinical characteristics were not significant for positive findings on the 68Ga-PSMA PET/CT scan.

Table 2

Clinical characteristics and association with positive 68Ga-PSMA PET/CT scans (n = 95).

Clinical Characteristics	Prediction in Logistic Regression Analysis
	Univariate analysis	Multivariate analysis
Age	NS	NS
N status	NS	NS
ISUP score	0.005	NS
Risk score	<0.005	NS
Number of positive sites	NS	NS
Initial treatment (RP vs. EBRT)	NS	NS
Adjuvant ADT	0.002	NS
Disease free interval	NS	NS
Lymph node metastases at initial treatment	NS	NS
PSADT	<0.0005	<0.0005
PSA at 68Ga-PSMA PET/CT	0.010	NS

Abbreviations as in Table 1. NS = not significant.

At the time of the 68Ga-PSMA PET/CT scan patients with PSADT <3 months more often had positive sites in regional lymph nodes or distant organs than patients with PSADT >12 months (p < 0.0005, chi2 test). Patients with a short period from diagnosis to PSA relapse <3 years had more metastatic sites than patients with a longer period from diagnosis to PSA relapse. The PSA level up to the 68Ga-PSMA PET/CT had a marked impact on the 68Ga-PSMA PET/CT findings. Additionally, PSADT at PSA relapse had a marked impact on the 68Ga-PSMA PET/CT findings.

Patients with metastatic sites on the 68Ga-PSMA PET/CT scan had significantly more multiple positive sites than had patients with positive sites only in the prostate bed (p > 0.0005, chi2 test). The odds ratio (OR) for PSADT was related with positive and negative 68Ga-PSMA PET/CT findings (beta coefficient −0.047, p <0.0005, pseudo R2 = 0.37). PSA up to the 68Ga-PSMA PET/CT scan had a significant association with extent of regional locations of positive sites on the 68Ga-PSMA PET/CT scan.

3.4. Salvage Treatment

After 68Ga-PSMA PET/CT, 7 patients with negative 68Ga-PSMA PET/CT findings were followed with active surveillance and 23 patients were treated with salvage radiotherapy. Of patients with positive sites on the 68Ga-PSMA PET/CT scan, 13 were given salvage radiotherapy, 30 were given chemotherapy with docetaxel, and 17 patients were given the third-generation AR pathway inhibitors abiraterone and enzalutamide.

3.5. Prediction of Overall Survival

After four years follow-up, 21 patients (22%) died. Table 3 shows the significant predictors of overall survival (OS). Risk score significantly predicted OS, as shown in Figure 2A. The most advanced regional locations of positive findings on the 68Ga-PSMA PET/CT scan significantly predicted OS (p = 0.0091, log rank test), as shown in Figure 2B. Regarding 68Ga-PSMA PET/CT, the number of positive sites had a significant impact on OS (p = 0.0001, log rank test), as shown in Figure 2C.

Table 3

Analyses of overall survival.

Predictive Factors	Cox Regression Analysis
	Univariate	Multiple
ISUP score	NS	-
Risk score	0.039	NS
Initial treatment	NS	-
Adjuvant ADT	NS	-
Interval from initial treatment to PSA recurrence	NS	-
PSA at 68Ga-PSMA PET/CT	NS	-
PSADT	NS	-
Most advanced regional location at 68Ga PSMA PET/CT	0.004	NS
No of sites on 68Ga-PSMA PET/CT	0.0001	0.0001

Figure 2

Overall survival after the 68Ga-PSMA PET/CT scan. (A) Shows that the risk score of the patients predicted overall survival. (B) Shows that the most advanced regional locations of positive sites on 68Ga-PSMA PET/CT predicted overall survival. PETno 0 denotes negative findings on 68Ga-PSMA PET/CT scans, PETno 1 denotes positive sites in the prostate bed, PETno 2 denotes positive sites in regional lymph nodes, and PETno 3 denotes positive findings in distant organs. (C) Shows that the number of positive sites on the 68Ga-PSMA PET/CT scan predicted overall survival.

In multiple Cox regression analysis, only the number of positive sites on the 68Ga-PSMA PET/CT scan significantly predicted OS, as shown in Table 3.

4. Discussion

Our study showed that the regional location and number of positive sites on theh 68Ga-PSMA PET/CT scan had impact on the treatment of the patients with PSA relapse and predicted OS. Especially important for our study was the observation that one of three clinical characteristics for high-risk PSA relapse, ISUP grade ≥ 4 was significantly associated with finding of metastatic sites on the 68Ga-PSMA PET/CT scan.

Further clinically important, our study showed that—in addition to high risk score—advanced regional locations and high number of positive sites on 68Ga-PSMA predicted impaired overall survival, a shown in Figure 3.

Figure 3

This figure summarizes the study in showing that the initial risk score and the regional locations and number of positive sites on 68Ga-PSMA-PET/CT scans predicted overall survival.

Francolini et al. also found that a short time to PSA relapse (2.5 years) increased the rate of positive sites in 68Ga-PSMA PET/CT findings [51]. Kulkarni et al. showed that patients with a high ISUP grade and a short PSADT had a high rate of 68Ga-PSMA PET/CT positive findings [52]. Additionally, a previous meta-analysis reported that a short PSADT at PSA relapse predicted many positive sites on 68Ga-PSMA PET/CT [53].

Hoffmann et al. reported that patients with PSA relapse had an S shaped relation between the PSA levels before 68Ga-PSMA PET/CT and the rate of positive findings on their 68Ga-PSMA PET/CT scans [18]. Patients with positive sites in regional lymph nodes and bones had higher median PSA values before 68Ga-PSMA PET/CT than those with positive sites in the prostate bed.

A key finding was that patients with a 68Ga-PSMA PET/CT positive site had a higher PSA level at restaging than patients with a negative finding, and that patients with a positive site in distant organs had a higher PSA level at the time of the restaging than the patients with positive sites in the prostate bed and regional lymph nodes.

Bashir et al. also showed using 68Ga-PSMA PET/CT that patients with PSA relapse more often had oligometastatic prostate cancer than polymetastatic prostate cancer [54]. Multiparametric MRI may better detect local relapse than 68Ga-PSMA PET/CT [55]. The background is that it may be difficult to differentiate between a local relapse and tracer excreted into the urinary bladder at the time of the imaging. Correspondingly, a publication of Emmett et al. indicated that patients with a negative 68Ga-PSMA PET/CT scan treated with salvage radiotherapy of the prostate bed had a better outcome than patients who were not treated with salvage radiotherapy [56].

Similarly, Celli et al. reported follow-up of 103 patients with negative 68Ga-PSMA PET/CT findings [57]. The patients were followed with active surveillance. Those with cancers of ISUP grades 4 and 5 had a relatively short median relapse-free survival (RFS) of 14 months, pointing to the risk of false negative findings with 68Ga-PSMA PET/CT.

Artibani et al. underlined that it is clinically important to salvage treatment in the phase of early PSA relapse and to distinguish between local and metastatic sites at PSA relapse [58]. Conventional imaging modalities do not allow the categorization of the recurrent site for patients with PSA relapse and PSA levels below 2 ng/mL. Restaging with 68Ga-PSMA PET/CT is crucial for decisions regarding the most relevant treatments for patients with early PSA relapse.

Another publication with three years of follow-up after 68Ga-PSMA PET/CT showed that 65% of patients with negative sites or positive sites only in the prostate bed had a three-year progression-free survival (PFS), whereas this number was lower (45%) for patients with positive sites outside the prostate bed [58]. The study underlines that the regional location of positive sites on restaging 68Ga-PSMA PET/CT has prognostic significance.

Further another previous publication showed that patients who were given salvage radiotherapy to the prostate bed when they had extremely low pretreatment PSA most often did not develop a new recurrence [59]. Previous publications reported salvage treatment for patients with PSA relapse based on 68Ga-PSMA PET/CT, as indicated in Figure 4. For up to two thirds of the patients with PSA relapse, treatment based on 68Ga-PSMA PET/CT differed from the treatment plans based on only conventional imaging modalities [60,61].

Figure 4

This figure summarizes how 68Ga-PSMA PET/CT findings may change treatment decisions for the salvage treatment of patients with PSA relapse

Our study provides relevant correlations with others regarding non-metastatic prostate cancer. Three large clinical trials used PSA >2 ng/mL and PSADT <10 months as inclusion criteria and showed a benefit when AR pathways inhibitors, enzalutamide (PROSPER trial), apalutamide (SPARTAN trial), and darolutamide was added to conventional ADT [62,63,64]. Importantly, our patients had the same range of pre-test PSA levels as had patients reported in the three trials of patients with non-metastatic prostate cancer. A previous study [65] like our study points to 68Ga-PSMA PET/CT detecting metastatic sites.

Our study also provides relevant correlations with others regarding the concept of oligometastatic prostate cancer. The stage is defined due to the findings with second generation imaging modalities such as choline and PSMA PET/CT. Some authors have used the information from the PET/CT scans to target the positive sites with precision EBRT with the aim to delay systemic treatment [66,67,68,69]. The overall survival with this approach has not been encouraging [70,71] compared with the results from systemic treatment with combined ADT and second-generation AR pathway inhibitors [62,63,64].

To the best of our knowledge, the prediction of outcome from number of positive sites on 68Ga-PSMA PET/CT scans for patients with PSA relapse has not been reported before. The finding can be validated in a complementary ongoing multicenter study.

Ongoing trials further are being undertaken evaluate the role of 68Ga-PSMA PET/CT in treatment decision-making processes [72]. Future trials may investigate whether another approach to patients with PSA relapse combining targeted radiotherapy and systemic treatment might improve OS.

Our study had limitations. 68Ga-PSMA PET/CT might have given some false negative findings for the prostate bed. The scans may also have given some false negative findings for pelvic lymph nodes due to undetected micrometastases with tumor diameters <5 mm [71,72]. Our study did not include initial staging at the initial treatment with 68Ga-PSMA PET/CT or the staging of patients with PSA relapse with 18F-PSMA PET/CT scans [73]. Our study did not evaluate PSMA PET/MRI, an alternative imaging modality that avoids the radioactivity exposure of the CT component of the PET/CT scans [74].

5. Conclusions

Most patients with PSA relapse after RP or EBRT have positive findings with 68Ga-PSMA PET/CT. The positive findings had implications for the salvage treatment and predicted overall survival.

6. Ethical Approval

All patients had given informed consent to undergo 68Ga-PSMA PET/CT and for their findings to be evaluated and published. The Science-Ethics committee of the University of Ankara, Turkey, approved the present analyses of the study group of patients as of 4 March 2021 (approval number 12-171-21).